RecruitingNCT05820802

High Dimensional Analysis of Immune Cells in Pediatric Patients

High Dimensional Analysis of Immune Cells Using scRNA-seq in Pediatric Patients With Allergic Reactions to Neuromuscular Blockers

Sponsor

Seoul National University Hospital

Enrollment

294 participants

Start Date

Apr 27, 2023

Study Type

OBSERVATIONAL

Conditions

Neuromuscular Blockade drug allergy

Summary

The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.

Eligibility

Min Age: 2 YearsMax Age: 18 Years

Inclusion Criteria1

Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.

Exclusion Criteria4

Patients who have received immunomodulators, immunosuppressants, etc.
Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.)
Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.)
Other cases where the Principal Investigator determines that it is difficult to conduct the study.

Interested in this trial?

Get notified about updates and connect with the research team.